#United Kingdom #pharmaceuticals #Norgine #Hengoed

Norgine's Bold Investment in Pharmaceutical Manufacturing

Norgine, a prominent name in the European pharmaceutical industry, has taken a substantial step to bolster its manufacturing capabilities with a new investment of £23 million at its facilities in Hengoed, Wales. This latest investment marks a milestone, bringing the total expenditure at the site to over £50 million since 2022. The funding, supported by the UK Government's Life Sciences Innovative Manufacturing Fund (LSIMF), is aimed at driving innovation and expansion in the region, significantly enhancing the company's production and supply chain resilience amid rising global market volatility.

This expansion is set to not only increase production capacity but also improve the site's warehousing facilities, energy efficiency, and quality control processes. The investment will create 44 skilled jobs, reinforcing Norgine's long-term manufacturing presence in Wales.

Jo Stevens, Secretary of State for Wales, expressed her enthusiasm about Norgine's decision, highlighting it as a clear endorsement of Wales' skilled workforce and a key contributor to the thriving life sciences sector in the region. She stated that government funding is facilitating businesses to grow, create high-paying jobs, and thrive in Wales, showcasing the success of international companies in the country.

Saulo Martiniano, the Chief Operating Officer at Norgine, commented on the importance of this investment in ensuring that scientific breakthroughs reach the patients who need them. He underscored that enhancing the Hengoed facility directly contributes to the resilience of UK and European health systems, particularly as the demand for reliable access to medicines becomes ever more critical.

Additionally, this expansion is part of a broader strategy by Norgine, which includes plans for further investments in the coming years to establish a robust supply chain and create an estimated 75 new permanent roles across manufacturing, quality assurance, and warehousing. This commitment reflects Norgine’s vision for sustainable growth and community engagement, evidenced by their ongoing educational and skill development initiatives in partnership with local institutions such as Cardiff University and regional colleges. These programs aim to equip the next generation of talent for the pharmaceutical manufacturing sector.

The Hengoed site, which employs over 600 skilled professionals, currently manages to supply around 50 million packs of medicines and medical devices each year. The facility operates on 100% low-carbon electricity, demonstrating Norgine’s dedication to sustainable manufacturing practices. This approach supports not just operational efficiency but also aligns with community and environmental standards.

As a mid-sized pharmaceutical entity based in the EU, Norgine boasts approximately 1,500 employees and generates around €650 million in annual sales. With an emphasis on addressing unmet medical needs, Norgine focuses its efforts on a range of health issues, from common conditions like constipation to severe rare diseases such as childhood cancer. The company's long history in the pharmaceutical landscape allows it to adeptly navigate complex pathways to deliver life-changing medicines to those in need across Europe, Australia, and New Zealand.

In conclusion, Norgine's investment in Hengoed not only signifies a strategic expansion for the company but also reinforces its crucial role in the pharmaceutical sector, building a sustainable, efficient, and community-oriented manufacturing ecosystem capable of meeting future healthcare demands. With this investment, Norgine continues to set a benchmark in the health sector, prioritizing innovation and patient-centric solutions in its operational approach.